rNanH与rPknG重组亚单位疫苗对小鼠伪结核棒状杆菌感染的免疫保护评价
本研究在Balb/c小鼠模型中评价伪结核棒状杆菌的rNanH和rPknG重组亚单位疫苗(含皂苷佐剂)。结果显示rNanH组在攻毒后存活率60%,显著高于rPknG组的20%,并诱导Th1型免疫应答。
要点
- rNanH加皂苷佐剂组攻毒后存活率60%,显著优于rPknG组的20%。
- rNanH组诱导Th1型免疫应答,rPknG组以IL-4产生为主。
- 两种重组蛋白均能显著提高总IgG、IgG1和IgG2a水平。
核心结论
- 含rNanH和皂苷的配方(G2)对小鼠伪结核棒状杆菌攻毒提供最佳保护,并诱导Th1免疫应答,可作为开发干酪性淋巴结炎有效疫苗的候选抗原。
研究设计与样本
- 小鼠接受两剂疫苗,间隔21天,末次免疫后21天以2×10^4 CFU/mL的伪结核棒状杆菌MIC-6株攻毒。
主要发现
- 第42天,G2和G3的总IgG、IgG1和IgG2a水平显著升高,且IgG2a水平高于IgG1。
- G3在第42天总IgG产量显著高于G2(p<0.05)。
- 仅G2中IL-17、TNF和IFN-γ的mRNA表达显著增加,仅G3显著产生IL-4;IL-10和IL-12在各组均无显著变化。
- 攻毒后存活率G3为20%,G2为60%(p<0.05)。
临床怎么用
- rNanH联合皂苷佐剂在小鼠中显示较好的保护效果和Th1免疫应答,支持其作为干酪性淋巴结炎疫苗候选抗原的进一步开发。
局限性
- 研究仅在小鼠模型中进行,样本量有限(每组10只),结果外推至其他动物或人类需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the economic and zoonotic relevance of caseous lymphadenitis, a competent immunoprophylaxis tool is still necessary. Here, we evaluated two putative virulence factors of Corynebacterium pseudotuberculosis, rNanH, and rPknG, as recombinant subunit vaccines in a murine model against the infection by C. pseudotuberculosis. Three groups of ten Balb/c mice each were inoculated with a sterile 0.9% saline solution (G1), rNanH (G2), or rPknG (G3) in formulations containing saponin as an adjuvant. The mice received two vaccine doses intercalated by a 21-day interval and were challenged with 2 × 104 CFU/mL of the C. pseudotuberculosis MIC-6 strain 21 days after the last immunization. The total IgG, IgG1, and IgG2a production levels increased significantly in the experimental groups (G2 and G3) on day 42. The highest levels of IgG2a antibodies in G2 and G3 were observed compared to IgG1 levels. G3 showed a significant (p < 0.05) humoral response through higher production of total IgG at day 42 when compared to G2. A significant increase of mRNA expression levels of interleukin (IL)-17, tumor necrosis factor, and interferon-γ was observed only in G2, while IL-4 was significantly produced only by G3. The levels of IL-10 and IL-12 obtained were not significant in any group. The survival rates after the challenge were 20% for G3 and 60% for G2 (p < 0.05). Our findings suggest that the formulation containing rNanH and saponin (G2) resulted in the best protection against the challenge and was able to elicit a Th1 immune response in mice, and can be considered as a promising antigen in the development of an effective vaccine against caseous lymphadenitis.
引用
- Thais de Oliveira Silva M, Barros de Pinho R, da Rocha Fonseca B, et al. NanH and PknG putative virulence factors as a recombinant subunit immunogen against Corynebacterium pseudotuberculosis infection in mice. Vaccine. 2020. PMID: 33190945. doi:10.1016/j.vaccine.2020.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。